Tobramycin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tobramycin" in English language version.

refsWebsite

Global rank English rank

17nih.gov

4^th place

7doi.org

2^nd place

2drugs.com

399^th place

333^rd place

2medicines.org.uk

3,823^rd place

2,387^th place

2europa.eu

68^th place

117^th place

2toku-e.com

low place

2clincalc.com

3,912^th place

2,496^th place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1books.google.com

3^rd place

1handle.net

102^nd place

76^th place

1web.archive.org

1^st place

1semanticscholar.org

11^th place

8^th place

1jstor.org

26^th place

20^th place

1harvard.edu

18^th place

17^th place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 507. ISBN 978-3-527-60749-5.{{cite book}}: CS1 maint: overridden setting (link)

canada.ca

"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Tobramycin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, et al. (May 1983). "Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin". Lancet. 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.
Neu HC (August 1976). "Tobramycin: an overview". The Journal of Infectious Diseases. 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.
Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis". Antimicrobial Agents and Chemotherapy. 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.
Yang G, Trylska J, Tor Y, McCammon JA (September 2006). "Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies". Journal of Medicinal Chemistry. 49 (18): 5478–90. doi:10.1021/jm060288o. PMID 16942021.
Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, et al. (April 2002). "Design of novel antibiotics that bind to the ribosomal acyltransfer site". Journal of the American Chemical Society. 124 (13): 3229–37. Bibcode:2002JAChS.124.3229H. doi:10.1021/ja011695m. PMID 11916405.{{cite journal}}: CS1 maint: overridden setting (link)
Kotra LP, Haddad J, Mobashery S (December 2000). "Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance". Antimicrobial Agents and Chemotherapy. 44 (12): 3249–56. doi:10.1128/aac.44.12.3249-3256.2000. PMC 90188. PMID 11083623.
Meylan S, Porter CB, Yang JH, Belenky P, Gutierrez A, Lobritz MA, et al. (February 2017). "Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control". Cell Chemical Biology. 24 (2): 195–206. doi:10.1016/j.chembiol.2016.12.015. PMC 5426816. PMID 28111098.{{cite journal}}: CS1 maint: overridden setting (link)

drugs.com

"Tobramycin Use During Pregnancy". Drugs.com. 11 November 2019. Retrieved 28 April 2020.
"Tobramycin ophthalmic Use During Pregnancy". Drugs.com. 24 December 2019. Retrieved 28 April 2020.

europa.eu

ema.europa.eu

"Tobi Podhaler EPAR". European Medicines Agency (EMA). 17 March 2003. Retrieved 10 August 2024.
"Tobi Podhaler". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.

handle.net

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

harvard.edu

ui.adsabs.harvard.edu

Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, et al. (April 2002). "Design of novel antibiotics that bind to the ribosomal acyltransfer site". Journal of the American Chemical Society. 124 (13): 3229–37. Bibcode:2002JAChS.124.3229H. doi:10.1021/ja011695m. PMID 11916405.{{cite journal}}: CS1 maint: overridden setting (link)

jstor.org

Neu HC (August 1976). "Tobramycin: an overview". The Journal of Infectious Diseases. 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.

medicines.org.uk

"Tobramycin 40mg/mL Injection – Summary of Product Characteristics (SmPC)". (emc). 9 October 2018. Retrieved 28 April 2020.
"Tobradex Eye Drops – Summary of Product Characteristics (SmPC)". (emc). 21 January 2020. Retrieved 28 April 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, et al. (May 1983). "Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin". Lancet. 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.
Neu HC (August 1976). "Tobramycin: an overview". The Journal of Infectious Diseases. 134 (Suppl): S3–19. doi:10.1093/infdis/134.supplement_1.s3. JSTOR 30106949. PMID 787451.
Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis". Antimicrobial Agents and Chemotherapy. 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.
Reyhanoglu G, Reddivari AK (January 2022). "Tobramycin". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31869159.
Yang G, Trylska J, Tor Y, McCammon JA (September 2006). "Binding of aminoglycosidic antibiotics to the oligonucleotide A-site model and 30S ribosomal subunit: Poisson-Boltzmann model, thermal denaturation, and fluorescence studies". Journal of Medicinal Chemistry. 49 (18): 5478–90. doi:10.1021/jm060288o. PMID 16942021.
Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Liu M, et al. (April 2002). "Design of novel antibiotics that bind to the ribosomal acyltransfer site". Journal of the American Chemical Society. 124 (13): 3229–37. Bibcode:2002JAChS.124.3229H. doi:10.1021/ja011695m. PMID 11916405.{{cite journal}}: CS1 maint: overridden setting (link)
Kotra LP, Haddad J, Mobashery S (December 2000). "Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance". Antimicrobial Agents and Chemotherapy. 44 (12): 3249–56. doi:10.1128/aac.44.12.3249-3256.2000. PMC 90188. PMID 11083623.
Meylan S, Porter CB, Yang JH, Belenky P, Gutierrez A, Lobritz MA, et al. (February 2017). "Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control". Cell Chemical Biology. 24 (2): 195–206. doi:10.1016/j.chembiol.2016.12.015. PMC 5426816. PMID 28111098.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Tobi- tobramycin solution". DailyMed. 5 October 2018. Retrieved 28 April 2020.
"Tobrex- tobramycin ointment". DailyMed. 16 September 2019. Retrieved 28 April 2020.
"Tobradex- tobramycin and dexamethasone ointment". DailyMed. 11 September 2019. Retrieved 28 April 2020.
"Tobradex- tobramycin and dexamethasone suspension/ drops". DailyMed. 9 September 2019. Retrieved 28 April 2020.
"Tobramycin- tobramycin sulfate injection, powder, for solution". DailyMed. 11 October 2019. Retrieved 28 April 2020.

ncbi.nlm.nih.gov

Pedersen SS, Jensen T, Osterhammel D, Osterhammel P (April 1987). "Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis". Antimicrobial Agents and Chemotherapy. 31 (4): 594–9. doi:10.1128/AAC.31.4.594. PMC 174783. PMID 3606063.
Reyhanoglu G, Reddivari AK (January 2022). "Tobramycin". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31869159.
Kotra LP, Haddad J, Mobashery S (December 2000). "Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance". Antimicrobial Agents and Chemotherapy. 44 (12): 3249–56. doi:10.1128/aac.44.12.3249-3256.2000. PMC 90188. PMID 11083623.
Meylan S, Porter CB, Yang JH, Belenky P, Gutierrez A, Lobritz MA, et al. (February 2017). "Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control". Cell Chemical Biology. 24 (2): 195–206. doi:10.1016/j.chembiol.2016.12.015. PMC 5426816. PMID 28111098.{{cite journal}}: CS1 maint: overridden setting (link)

semanticscholar.org

api.semanticscholar.org

Lerner AM, Reyes MP, Cone LA, Blair DC, Jansen W, Wright GE, et al. (May 1983). "Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin". Lancet. 1 (8334): 1123–6. doi:10.1016/S0140-6736(83)92864-7. PMID 6133153. S2CID 8303933.

tga.gov.au

"Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

toku-e.com

"Tobramycin" (PDF). Toku-E. 12 January 2010. Retrieved 11 June 2012.
"Tobramycin Susceptibility and Minimum Inhibitory Concentration (MIC) Data" (PDF). Toku-E.

web.archive.org

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.